SCHEMBL15036166

SCHEMBL15036166

CC#Cc1cc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n(Cc2ncccc2C)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 1/20 0.53
CDK4 P11802 10/20 0.52
CCND1 P24385 9/20 0.52
CCND3 P30281 9/20 0.52
CCND2 P30279 8/20 0.52
FGFR1 P11362 3/20 0.51
CCNA2 P20248 3/20 0.51
CDK2 P24941 3/20 0.51
CDK1 P06493 2/20 0.51
CCNB1 P14635 2/20 0.51
CCNE1 P24864 2/20 0.51
CDK9 P50750 2/20 0.51
CDK6 Q00534 2/20 0.51
NUAK1 O60285 2/20 0.51
MARK3 P27448 2/20 0.51
MARK2 Q7KZI7 2/20 0.51
MARK4 Q96L34 2/20 0.51
NUAK2 Q9H093 2/20 0.51
MARK1 Q9P0L2 2/20 0.51
FLT3 P36888 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041892 0.89 WEE1 (0.50) WEE1CDK4CCND1CCND3CCND2
SCHEMBL15036197 0.89 WEE1 (0.54) WEE1CDK4CCND1CCND3CCND2
SCHEMBL15258303 0.85 WEE1 (0.48) WEE1CDK4CCND1CCND3CCND2
SCHEMBL10192693 0.84 CDK4 (0.70) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL15258239 0.84 WEE1 (0.57) WEE1CDK4CCND1CCND3CCND2
SCHEMBL15036178 0.83 CDK4 (0.59) WEE1CDK4CCND1CCND3CCND2
SCHEMBL15036193 0.82 WEE1 (0.54) WEE1CDK4CCND1CCND3CCND2
SCHEMBL15258235 0.82 PAK3 (0.53) WEE1CDK4CCND1CCND3FGFR1
SCHEMBL15617434 0.81 WEE1 (0.51) WEE1CDK4CCND1CCND3CCND2
SCHEMBL15036191 0.81 WEE1 (0.51) WEE1CDK4CCND1CCND3CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680099-B2 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-03-25 US disclosed
US-20130245012-A1 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-19 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245012-A1 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK6, PAK3 WEE1 763/4885CDK4 397/4885CCND1 3936/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 WEE1 545/4885CDK4 404/4885CCND1 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.